Key Details
Annual Revenue
$194.13 MAnnual EPS
-$1.61Annual ROE
-2255.01%Annual Debt To Equity
-13.53Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 24, 2023Recent annual earnings:
Feb 24, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with AERI included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Aerie Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Aerie Pharmaceuticals?
- What is the ticker symbol for Aerie Pharmaceuticals?
- Does Aerie Pharmaceuticals pay dividends?
- What sector is Aerie Pharmaceuticals in?
- What industry is Aerie Pharmaceuticals in?
- What country is Aerie Pharmaceuticals based in?
- When did Aerie Pharmaceuticals go public?
- Is Aerie Pharmaceuticals in the S&P 500?
- Is Aerie Pharmaceuticals in the NASDAQ 100?
- Is Aerie Pharmaceuticals in the Dow Jones?
- When was Aerie Pharmaceuticals's last earnings report?
- When does Aerie Pharmaceuticals report earnings?
What is the primary business of Aerie Pharmaceuticals?
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
What is the ticker symbol for Aerie Pharmaceuticals?
The ticker symbol for Aerie Pharmaceuticals is NASDAQ:AERI
Does Aerie Pharmaceuticals pay dividends?
No, Aerie Pharmaceuticals does not pay dividends
What sector is Aerie Pharmaceuticals in?
Aerie Pharmaceuticals is in the Healthcare sector
What industry is Aerie Pharmaceuticals in?
Aerie Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Aerie Pharmaceuticals based in?
Aerie Pharmaceuticals is headquartered in United States
When did Aerie Pharmaceuticals go public?
Aerie Pharmaceuticals's initial public offering (IPO) was on 25 October 2013
Is Aerie Pharmaceuticals in the S&P 500?
No, Aerie Pharmaceuticals is not included in the S&P 500 index
Is Aerie Pharmaceuticals in the NASDAQ 100?
No, Aerie Pharmaceuticals is not included in the NASDAQ 100 index
Is Aerie Pharmaceuticals in the Dow Jones?
No, Aerie Pharmaceuticals is not included in the Dow Jones index
When was Aerie Pharmaceuticals's last earnings report?
Aerie Pharmaceuticals's most recent earnings report was on 24 February 2023
When does Aerie Pharmaceuticals report earnings?
The date for Aerie Pharmaceuticals's next earnings report has not been announced yet